Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the month of May 2004. The registrant is a foreign private issuer based in South Melbourne, Australia. The filing primarily serves as a new issue announcement and application for quotation of additional securities on the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, or debt figures. It focuses exclusively on capital structure changes resulting from option exercises.
- Securities Issued: 200,000 Ordinary Shares.
- Issue Price: $0.50 per share.
- Total Consideration: $100,000 (calculated from 200,000 shares at $0.50).
- Purpose: Exercise of options (PBTAO).
- Post-Issue Quoted Shares: 75,159,380 Ordinary Shares.
- Outstanding Options (Unquoted):
- 19,750,000 Options (PBTAK) exercisable at $0.50 by Dec 1, 2004.
- 897,167 Employee & Consultant Options (PBTAO) exercisable at $0.50 by June 30, 2005.
- 10,000 Employee & Consultant Options (PBTAI) exercisable at $1.50 by June 30, 2005.
- 200,000 Options (PBTAQ) exercisable at $0.50 by Oct 1, 2005.
Material Changes
The primary material change is the issuance of 200,000 new ordinary shares following the exercise of options. These new shares rank pari passu with existing ordinary shares from the date of allotment. The total number of quoted ordinary shares on the ASX increased to 75,159,380. The dividend policy remains unchanged.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes standard legal warranties to the ASX regarding the legality of the issue and compliance with the Corporations Act. No specific risks or contingencies are detailed beyond the standard disclosure requirements for a new issue announcement.
Investor Verification Checklist
- Verify the total number of outstanding options and their respective expiry dates and exercise prices to assess potential future dilution.
- Confirm the cash proceeds of $100,000 from the option exercise and how these funds are being utilized (not specified in this filing).
- Check subsequent filings for any financial performance data, as this Form 6-K contains no operational or financial results.
- Review the company's current cash position to determine liquidity status, as this filing does not report cash balances.